Elevance Health Inc. (ELV) Tops Q2 EPS by 124c, raises guidance

Elevance Health Inc. (NYSE: ELV) reported Q2 EPS of $7.45, $1.24 better than the analyst estimate of $6.21. Revenue for the quarter came in at $49.8 billion versus the consensus estimate of $48.63 billion.

GUIDANCE:

Elevance Health Inc. sees FY2026 EPS of at least $27.00, versus the consensus of $26.91.

For earnings history and earnings-related data on Elevance Health Inc. (ELV) click here.

You May Also Be Interested In

• Laird Superfood, Inc. (LSF) Misses Q2 EPS by 22c ; Offers Guidance
• The Elmet Group Co. (ELMT) Reports Q2 EPS of $0.18
• Xos, Inc (XOS) Tops Q2 EPS by 5c